Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587158 · ClinicalTrials.gov registry record · NA
Oral Paricalcitol in Kidney Transplant Recipients
A NA study of Transplant;Failure,Kidney and Hyperparathyroidism, Secondary, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT00587158: Completed NA study of Transplant;Failure,Kidney and Hyperparathyroidism, Secondary, sponsored by Mayo Clinic.
NCT00587158 is a NA study of Transplant;Failure,Kidney and Hyperparathyroidism, Secondary that has completed, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 211-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587158, a NA study of Transplant;Failure,Kidney and Hyperparathyroidism, Secondary, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this medication. The main possible benefits being studied are: * Lower risk for overactive parathyroid glands after kidney transplantation. * Lower risk of low bone density in the spine and hip after kidney transplantation. By dividing patients in the study into a group receiving Zemplar® and a group not receiving Zemplar®, it will be possible to understand the good and bad effects of Zemplar® during the first year after a kidney transplant.
Primary Outcome
Parathyroid hormone (PTH) is a measure of how well the parathyroid gland is working and is measured by a blood test. Hyperparathyroidism (increased PTH) is defined as PTH blood value greater than 65 picograms/milliliter in the absence of hypocalcemia (low calcium) or if the subject had a parathyroidectomy (surgical removal of parathyroid glands) during the first year post-transplant.
Conditions Studied
Interventions
- DRUG Paricalcitol
- OTHER Corticosteroid Avoidance Immune Suppression Protocol
Study Locations (2)
Arizona
- Mayo Clinic - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT00587158 record still lists
NCT00587158 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 211-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Transplant;Failure,Kidney appearing as the primary indexed condition, and to 2 interventions - of which Paricalcitol is the first listed.
NCT00587158 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00587158 about?
NCT00587158 is a clinical study titled "Oral Paricalcitol in Kidney Transplant Recipients". This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this medication. The main possible benefits being studied are: * Lower risk for over...
What is the current status of trial NCT00587158?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2007-01. Estimated completion is 2011-11.
What conditions does trial NCT00587158 study?
This clinical trial studies the following conditions: Transplant;Failure,Kidney, Hyperparathyroidism, Secondary, Renal Disease, End Stage.
What interventions are being tested in trial NCT00587158?
The interventions under investigation include: Paricalcitol (DRUG), Corticosteroid Avoidance Immune Suppression Protocol (OTHER).
Who is sponsoring clinical trial NCT00587158?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00587158 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant;Failure,Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00587158's enrollment target sits among peer trials
100 4th of 8 higher than 5 of 8 other Transplant;Failure,Kidney trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Transplant;Failure,Kidney trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abdominal Wall Transplant
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
RECRUITING · NA
-
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
RECRUITING · Phase 4
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Quality of Life in Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia